

ORLICA 60

For the use of a Registered Medical Practitioner or a Hospital or Laboratory only
Abbreviated Prescribing information for Orlica 60 (Orlistat Capsules) [Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: Orlistat is a lipase inhibitor for obesity management that acts by inhibiting the absorption of dietary fats.

INDICATION: for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. And also indicated to reduce the risk for weight regain after prior weight loss.

DOSAGE AND ADMINISTRATION: The dosage of orlistat for the management of obesity and weight regain in adults is 120 mg 3 times daily with each main meal containing fat.

CONTRINDICATIONS: patients with chronic malabsorption syndrome or cholestasis, and in patients with known hypersensitivity to orlistat or to any component of this product.

WARNINGS & PRECAUTIONS: Organic causes of obesity (e.g., hypothyroidism) should be excluded before prescribing orlistat. orlistat and cyclosporine should not be coadministered. To reduce the chance of a drug-drug interaction, cyclosporine should be taken at least 2 hours before or after orlistat in patients taking both drugs. Gastrointestinal events may increase when orlistat is taken with a diet high in fat (>30% total daily calories from fat).

ADVERSE REACTIONS: Oily spotting, flatulence with discharge, fecal urgency, oily evacuation, increased defecation, fecal incontinence, oily rectal leakage, upper respiratory infection, steatorrhea, gingival disorders, nausea, rectal irritation and tooth disorder.

MARKETED BY:



TORRENT PHARMACEUTICALS LTD.
Torrent House, Off Ashram Road,
Ahmedabad-380 009, INDIA

IN/ ORLICA 60 /Oct-2015/01/AbPI

(Additional information is available on request)